Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to commence in Q1 2021 with final reporting in Q1 2022. AKP-02 is an antipsoriasis medicine that combines […]
Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent role as Head of Startup Programs at Chalmers Ventures. Stina will take up her position on September 2, 2020. Lipidor recently announced an updated plan to increase the rate of […]
The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at 11:00 a.m. CET. 13.00 at Karolinska Institutet Science Park, Fogdevreten 2 in Solna. Voting rights registration begins at 12.30 p.m. and will cease when the meeting is opened. The Company continues to closely […]
Lipidor AB ("Lipidor" or the “Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. On June 30, Emollivet's Extraordinary General Meeting resolved on a directed new share issue of SEK 4 million, conditional on the approval of Lipidor's […]
Lipidor AB held its Annual General Meeting (“AGM”) today, on the 11 June 2020, in Solna. The AGM elected the Chairman-elect of the Board, Fredrik Sjövall, as Chairman of the meeting. The AGM resolved in all proposed items in accordance with the proposals previously announced by the Board of Directors or the shareholders. A summary […]
Today, Lipidor AB publishes its interim report for the period January – March 2020. The Q1 report is available on the company's website lipidor.se (http://www.lipidor.se/) and in the attached pdf. Summary of the interim report – first quarter 2020 Positive results from the Phase III study of AKP01 validate AKVANO®, the company's patented lipid-based technology. Lipidor […]
Today, Lipidor AB announces that the company will publish its annual report for the financial year 2019. The annual report is available on the company's website lipidor.se and in the attached pdf. For more information, please contact Ola Holmlund, CEO Phone: +46 72 50 70 369 E-mail: ola.holmlund@lipidor.se Certified Adviser Corpura Fondkommission AB Telephone: +46 76 85 […]
The shareholders of Lipidor AB (publ) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on June 11, 2020 at 1.00pm at Karolinska Institutet Science Park, Fogdevreten 2 in Solna. Voting registration will open at 12.30pm and close when the AGM begins. The Company continues to closely monitor the situation […]
In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions with pharmaceutical companies, the Board of Lipidor submits an updated project plan together with prioritization of the company's project portfolio. In January 2020, Lipidor announced positive results from the completed Phase III study […]
In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have suffered from supply shortages. Lipidor (Nasdaq First North: LIPI) has previously developed a spray for hand and skin disinfection, called Skin Disinfection Spray, based on its patented technology. The company has now decided […]